← All indications
Toxemia
A condition produced by the presence of toxins or other harmful substances in the BLOOD.
Subtype terms (1)
More specific conditions that are subtypes of Toxemia in the MeSH hierarchy.
- Endotoxemia
55 drugs (26 approved, 29 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (2)
Phase 3 trials (1)
Organizations
Organization Involved with Phase 4 Indications (61)
- Abbott
- Fresenius
- Gilead Sciences
- AstraZeneca
- Eli Lilly
- Techpool Bio-Pharma Co., Ltd.
- Tianjin Chase Sun Pharmaceutical Co., LTD
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS)
- Sunnybrook Health Sciences Centre
- Central South University
- Ain Shams University
- CAMC Health System
- Centre Hospitalier Universitaire de Nīmes
- University of London
- Emory University
- Fernandes Tavora Hospital
- Li Shin Hospital
- Mansoura University
- Los Angeles Biomedical Research Institute
- Ohio State University
- Onze Lieve Vrouw Hospital
- Osaka City University
- Sapporo Medical University
- Sir Takhtasinhji General Hospital
- Tohoku University
- University of Florida
- University of Michigan
- University of Plymouth
- University of Toronto
- +31 more
Organization Involved with Phase 3 Indications (113)
- Symyoo
- Eisai
- Takeda
- Green Cross Corporation
- Novo Nordisk
- ICOS
- Bayer
- Biosyn
- Biosynexus Incorporated
- Chiesi
- SciClone Pharmaceuticals
- Suntory Pharmaceutical
- Agennix
- PENTA Foundation
- Wu Jieping Medical Foundation
- Save the Children
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- United States Air Force
- World Health Organization
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
- Maastricht University
- University of Pittsburgh
- Aragon Institute of Health Sciences
- Boston University
- Case Western Reserve University
- Chulalongkorn University
- Cornell University
- Harvard University
- +83 more
Organization Involved with Phase 2 Indications (50)
- Accentia Biopharmaceuticals
- Cato Research
- AM-Pharma
- Artisan Pharma, Inc.
- Baxalta
- GlaxoSmithKline
- Hamilton Health Sciences Corporation
- Parexel
- German Research Foundation
- Medical Research Council
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- University of Roma La Sapienza
- Shanghai Changzheng Hospital
- Baylor University
- Instituto Mexicano del Seguro Social
- Saint Francis Hospital and Medical Center
- University of Liverpool
- University of Manchester
- University of Ottawa
- University of Pecs
- University of Aberdeen
- University of Bristol
- Virginia Commonwealth University
- University of British Columbia
- University of Chicago
- University of Cincinnati
- Vanderbilt University
- University of Rwanda
- University of Limoges
- +20 more
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (28)
- Inhibitex
- Medical University of Graz
- Albert Schweitzer Hospital
- Changi General Hospital
- Mahidol University
- McGill University
- Nanjing University
- Queen's University, Belfast
- Fujian Medical University
- Institute of Liver and Biliary Sciences, India
- Tel Aviv University
- University of Amsterdam
- Free University of Amsterdam
- Government of Mexico
- University of Lyon
- University of Ostrava
- Kowng Wah Hospital
- University of Tuebingen
- The Physicians' Services Incorporated Foundation
- Fonds NutsOhra
- Nederlandse Internisten Vereniging ( Dutch Association of Internists)
- Government of Hong Kong
- Dhaka Shishu Hospital
- Government of Singapore
- Chinese Academy of Medical Sciences
- Città della Speranza, Padova
- Universidad de Cordoba
- Jinlin University